A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks.
Recent Posts
- This inflation-focused ETF may be in a sweet spot
- Bronze bust honoring the late Charlie Munger wowed crowd in Omaha at Berkshire meeting
- The rule capping credit card late fees at $8 is on hold — here’s what it means for you
- Jim Simons, billionaire quantitative investing pioneer who generated eye-popping returns, dies at 86
- Sweetgreen shares soar 35% after company beats revenue expectations
Recent Comments